<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469170</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 011</org_study_id>
    <nct_id>NCT00469170</nct_id>
  </id_info>
  <brief_title>A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method</brief_title>
  <official_title>A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method for the Prevention of HIV Infection in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a multi-centre, open-label crossover study to assess the safety and
      acceptability of a silicone elastomer vaginal ring (containing no drug) when inserted for a
      12 week period in 200 healthy, sexually active women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary measure of acceptability will be defined as the proportion of women indicating that they would use the study product if it is found to prevent HIV.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary measure of safety will be the proportion of women who have abnormal observations during the pelvic/speculum examinations and the proportion of women who experience adverse events</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaginal ring first 12 weeks &amp; observational safety last 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>observational safety first 12 weeks &amp; vaginal ring last 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intravaginal ring</intervention_name>
    <description>silicone elastomer intravaginal ring containing no drug product</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age 18-35 years

          -  Willing and able to provide written informed consent

          -  HIV-uninfected and otherwise healthy

          -  Self-reported sexually active

          -  On a stable hormonal contraceptive regimen

          -  Regular menstrual cycle

          -  Willing to refrain from use of vaginal products or objects during the study

        Exclusion Criteria:

          -  Currently pregnant or last pregnancy within 3 months prior to enrollment

          -  Currently breast-feeding

          -  Participated in any other research study within 30 days prior to enrollment;

          -  Symptomatic untreated vaginal infections within 2 weeks prior to enrollment

          -  Presence of abnormal physical finding on the vulva, vaginal walls or cervix

          -  History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,
             urethral obstruction;

          -  Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than
             for infection), or further evaluation

          -  Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or
             following vaginal intercourse, or gynecologic surgery within 90 days prior to
             enrollment

          -  Any serious acute, chronic or progressive disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Annalene Nel</last_name>
    <role>Study Director</role>
    <affiliation>IPM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Health &amp; HIV Research Unit - Sheshisani IPM Clinic</name>
      <address>
        <city>Yeoville</city>
        <state>Johannesburg</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South African Medical Research Council</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu Natal</state>
        <zip>4067</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation, Masiphumelele</name>
      <address>
        <city>Cape Town</city>
        <zip>7975</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Reproductive Health Program</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Tanzania</country>
  </location_countries>
  <removed_countries>
    <country>Kenya</country>
  </removed_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>November 10, 2010</last_update_submitted>
  <last_update_submitted_qc>November 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Annalene Nel</name_title>
    <organization>International Partnership for Microbicides</organization>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HIV seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

